Abstract
We describe two systemic sclerosis (SSc) patients with isolated pulmonary arterial hypertension (PAH) who were given treatment with 50 mg oral sildenafil per day. We evaluated the efficacy of oral sildenafil for isolated PAH in SSc patients by direct assessment with cardiac catheterization before and 6 months after the initiation of sildenafil. Right-heart catheterization demonstrated decreased mean pulmonary artery pressure, decreased pulmonary vascular resistance, and increased cardiac output after treatment with sildenafil. Brain natriuretic peptide levels were gradually decreased. The 6-min walking distance was greatly extended. Moreover, the physical conditions of both patients were much improved. We recognized no adverse events. We propose that oral sildenafil may be beneficial as a selective pulmonary vasodilator and as long-term treatment in SSc patients with isolated PAH.
This is a preview of subscription content, log in via an institution to check access.
References
Coghlan JG, Mukerjee D (2001) The heart and pulmonary vasculature in scleroderma: clinical features and pathobiology. Curr Opin Rheumatol 13:495–499
Stupi AM, Steen VD, Owens GR, Barnes EL, Rodnan GP, Medsger TA Jr (1986) Pulmonary hypertension in the CREST syndrome variant of systemic sclerosis. Arthritis Rheum 29:515–524
Koh ET, Lee P, Gladman DD, Abu-Shakra M (1996) Pulmonary hypertension in systemic sclerosis: an analysis of 17 patients. Br J Rheumatol 35:989–993
Prasad S, Wilkinson J, Gatzoulis MA (2000) Sildenafil in primary pulmonary hypertension. N Engl J Med 343:1342
Ghofrani HA, Wiedemann R, Rose F, Schermuly RT, Olschewski H, Weissmann N, Gunther A, Walmrath D, Seeger W, Grimminger F (2002) Sildenafil for treatment of lung fibrosis and pulmonary hypertension: a randomised controlled trial. Lancet 360:895–900
Rosenkranz S, Diet F, Karasch T, Weihrauch J, Wassermann K, Erdmann E (2003) Sildenafil improved pulmonary hypertension and peripheral blood flow in a patient with scleroderma-associated lung fibrosis and the Raynaud phenomenon. Ann Intern Med 139:871–873
Watanabe H, Ohashi K, Takeuchi K, Yamashita K, Yokoyama T, Tran QK, Satoh H, Terada H, Ohashi H, Hayashi H (2002) Sildenafil for primary and secondary pulmonary hypertension. Clin Pharmacol Ther 71:398–402
Ahn HS, Foster M, Cable M, Pitts BJ, Sybertz EJ (1991) Ca/CaM-stimulated and cGMP-specific phosphodiesterases in vascular and non-vascular tissues. Adv Exp Med Biol 308:191–197
Olschewski H, Ghofrani HA, Walmrath D, Schermuly R, Temmesfeld-Wollbruck B, Grimminger F, Seeger W (1999) Inhaled prostacyclin and iloprost in severe pulmonary hypertension secondary to lung fibrosis. Am J Respir Crit Care Med 160:600–607
Cheitlin MD, Hutter AM Jr, Brindis RG, Ganz P, Kaul S, Russell RO Jr, Zusman RM (1999) Use of sildenafil (Viagra) in patients with cardiovascular disease. Technology and practice executive committee. Circulation 99:168–177
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Hayakawa, I., Shirasaki, F., Hirano, T. et al. Successful treatment with sildenafil in systemic sclerosis patients with isolated pulmonary arterial hypertension: two case reports. Rheumatol Int 26, 270–273 (2006). https://doi.org/10.1007/s00296-005-0613-y
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00296-005-0613-y